Category: Companies

Phillips 66 (PSX): Under The Radar Now

Piper Sandler raised the price target for the Phillips 66 (NYSE:PSX) stock from “an Overweight” to “a Neutral”. The rating was released on April 01,

Risky, but rewarding: Citizens Financial Group Inc. (CFG)

Compass Point raised the price target for the Citizens Financial Group Inc. (NYSE:CFG) stock from “a Neutral” to “a Buy”. The rating was released on

A finalist for your portfolio: Futu Holdings Limited (FUTU)

BofA Securities raised the price target for the Futu Holdings Limited (NASDAQ:FUTU) stock to “a Buy”. The rating was released on April 26, 2021. Historical

With a normalized view, Lloyds Banking Group plc (LYG)’s stock looks extremely Investable

Redburn raised the price target for the Lloyds Banking Group plc (NYSE:LYG) stock from “a Sell” to “a Neutral”. The rating was released on May

Sabre Corporation (SABR): Current Levels Attractive However Proceed With Caution

Morgan Stanley raised the price target for the Sabre Corporation (NASDAQ:SABR) stock from “an Overweight” to “an Equal-weight”. The rating was released on March 16,

Comstock Holding Companies Inc. (CHCI): Price Seems Unaltered

Robert W. Baird raised the price target for the Comstock Holding Companies Inc. (NASDAQ:CHCI) stock from “an Underperform” to “a Neutral”. The rating was released

Catalysts for shares to shoot up: AIkido Pharma Inc. (AIKI)

Historical Earnings Surprises and Revenue Forecasts It appears that the average earnings per share estimate for the current quarter (ending in Mar 2014) is $0.

Diversification of risks with a Double-Digit: Boston Scientific Corporation (BSX)

Needham raised the price target for the Boston Scientific Corporation (NYSE:BSX) stock from “a Buy” to “a Hold”. The rating was released on May 26,

Akebia Therapeutics Inc. (AKBA): Poised for growth over the next few years

Cantor Fitzgerald raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “an Overweight”. The rating was released on March 08, 2021. The

Signs of improvement in Hepion Pharmaceuticals Inc. (HEPA)’s stock price will boost it

ROTH Capital raised the price target for the Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) stock to “a Buy”. The rating was released on July 20, 2020. Historical

BOVNEWS

BOVNews.com was originated in 2018 as a Company. Our team comprises Analysts and writers with the knowledge and expertise of Stock Markets and other sectors of Finance. The foremost objective is to deliver impartial opinion and detailed analysis on stock and markets. Our Research team is always keen to stay update on market highlights, earnings reports, mergers and acquisitions, analyst opinions, and pass on their knowledge and expertise to our reader.

Quick Links

Join our morning newsletter

Get the hottest stocks to trade every day before the market opens 100% free.